Glycemic Effects of Postmenopausal Hormone Therapy: The Heart and Estrogen/progestin Replacement Study: A Randomized, Double-Blind, Placebo-Controlled Trial

By A. Kanaya, D. Herrington, E. Vittinghoff, Feng Lin, D. Grady, V. Bittner, J. Cauley, E. Barrett-Connor. Annals of Internal Medicine, 2003

621 citations recorded by the source corpus.

Subfields: Food Science, Materials Chemistry

View Paper: https://www.semanticscholar.org/paper/0e2ee9cd0e60d600972ceb2030f968a24eac11fd

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

1. D. Dabelea
2. Amy J. Steig
3. R. V. Van Pelt
4. T. Hernandez
5. M. Cornier
6. N. Stob
7. R. Lindstrom
8. Hong Wang

Citations in the corpus

• The metabolic syndrome. (2008, background): “Nevertheless, estrogen replacement in postmenopausal women has been shown to improve many components of the MetS, such as abdominal adiposity, HDL-C, and fasting glucose (461–464) and to lower the incidence of T2D (462, 465, 466).”
• The 2012 Hormone Therapy Position Statement of The North American Menopause Society (2012, neutral): “89).(70) In the WHI ET trial, there was a 12% reduction (HR, 0.”